Premarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Premarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions"

Transcription

1 FDLI s Introduction to Medical Device Law and Regulation: Understanding How FDA Regulates the Medical Device Industry October 28-29, 2002 The Westin Grand Hotel Washington, D.C. Premarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions presented by Suzan Onel, Partner Kirkpatrick & Lockhart, LLP 1800 Massachusetts Ave., N.W. Washington, D.C Phone: Fax: DC v

2 PREMARKET APPROVAL APPLICATIONS (PMAs), PRODUCT DEVELOPMENT PROTOCOLS (PDPs), AND HUMANITARIAN DEVICE EXEMPTIONS Suzan Onel, Esq. I. PMA REVIEW (FDCA 515 (21 U.S.C. 360(e)); 21 C.F.R. Part 814) A. Overview. 1. Standard: Reasonable Assurance Of Safety and Effectiveness. 2. Filing Date Is Date FDA Receives Complete PMA. 3. Clock Is 180-Day Review Time. 4. Substantial Changes Will Restart The Clock. 5. Review By FDA Personnel And Possibly Referred To FDA Advisory Committee. 6. FDA Notifies Applicant Of Approval By Letter. 7. Notice Announcing The Decision And Availability Of Summary Of Safety And Effectiveness Data Used To Be Published In Federal Register, Now On Internet. B. Early Collaboration Meetings. 1. Determination Meeting Type Of Scientific Evidence That Will Be Required. FDCA 513(a)(3)(D). 2. Agreement Meeting Pre-IDE Meeting To Agree On Investigational Plan. FDCA 520(g)(7). 3. Binding On The Agency Unless Contrary To Public Health. 4. Early Collaboration Meetings Under the FDA Modernization Act (FDAMA), Guidance for Industry and CDRH Staff (Feb. 19, 1998) [Exhibit 1] C. PMA Application Should Contain (21 C.F.R ): See PMA Manual at and PMA Elements Used [Exhibit 2] 1. Name And Address Of Applicant. 2

3 2. Comprehensive Summary. 3. Complete Description Of The Device Including Photographs And Drawings. 4. Full Reports Of Investigations On Safety And Effectiveness. 5. Components. 6. Methods And Controls Used For Manufacturing Or Processing. 7. Reference To Any Performance Standard Under 21 U.S.C Bibliography Of All Publications. 9. Summary Of Unpublished Information. 10. Statement That Nonclinical Studies Meet FDA Requirements (21 C.F.R. 58). 11. Summary Of Clinical And Nonclinical Investigation. 12. Investigator Financial Disclosure Or Certification 13. Sample (When Reasonable). 14. Labeling, Literature And Installation Instructions. 15. An Environmental Assessment. 16. If Only One Investigator Has Participated, A Justification That A Single Investigator Was Sufficient To Demonstrate Safety And Effectiveness Of Device. D. Filing The PMA Application. 1. Send To: Document Mail Center Food and Drug Administration HFZ Corporate Blvd. Rockville, MD (301) FDA Will Acknowledge Receipt And Provide Unique Application Number. 3. Only Authorized Person Submitting Application Can Obtain Information. 3

4 4. FDA, By Regulation, May Take 45 Days To Review Application To Determine If Complete. If Filed, FDA Begins Substantive Review. E. FDA Refusal To File PMA. 1. FDA May By Letter Cite Deficiencies In PMA And Refuse To Accept For Filing. 2. Sponsor May Contest Deficiencies. 3. Sponsor May, Within 10 Working Days, Request Informal Conference With Office Of Device Evaluation (ODE). 4. ODE Will Hold An Informal Conference Within 10 Working Days Of Its Receipt Of Sponsor's Request. 5. ODE Will Advise Sponsor Within 5 Working Days After Conference If PMA To Be Filed. 6. Sponsor May Request Reconsideration By Director Of CDRH. 7. Guidance Document -- Center For Devices And Radiological Health s Premarket Approval Application (PMA) Refuse To File Policy (6/30/93). F. Scope Of Review Limited To Conditions Of Use Submitted In Proposed Labeling (FDCA 515(d)(1)(A)). G. Review By Advisory Committee (FDCA 515(c)(2)). 1. FDA May Refer PMA To Advisory Committee On Its Own Initiative Or Upon The Request Of Applicant. 2. Meeting On PMA Is Public Except for Discussion of Confidential Information. 3. Panel Must Provide Report And Recommendation On PMA To FDA. H. Planning For And Meeting With Panel. 1 Obtain From Executive Secretary Copies Of All Material Submitted To Panel -- Pursuant To 21 C.F.R Obtain Information Regarding Panel Consultants. 3 Attend Public Meeting Or Obtain Transcript From Prior Panel Meetings. 4 FDAMA Reforms (FDCA 513(b)(6)(A)). a. Same Access To Data And Information As FDA; 4

5 b. Same Opportunity To Submit Additional Information As FDA; c. Same Opportunity To Participate As FDA; d. FDA Must Notify Applicant In Writing After Making Decision, Detailed Reasons For Variation From Panel Recommendations. e. Guidance on Amended Procedures for Advisory Panel Meetings (Jan. 26, 1999). I. Day-100 Meeting (FDCA 515(d)(3)). 1. Meeting To Discuss Status Of Review. 2. Must Be Requested Either When The PMA Is Filed Or No Later Than 70 Days After Filing. See Guidance on PMA Interative Procedures for Day- 100 Meetings and Subsequent Deficiencies for Use by CDRH and Industry (Feb. 19, 1998). J. Approval/Denial Of PMA. 1. Approval Order (21 C.F.R (d)). 2. Approvable Letter (21 C.F.R (e)). 3. Not Approvable Letter (21 C.F.R (f)). 4. Denial Order (21 C.F.R ) With A Finding Of: K. Modular PMAs. a. Lack Of Reasonable Assurance Of Safety Or Effectiveness. b. Lack Of GMP In Manufacturing. c. Labeling False And/Or Misleading. d. Failure To Conform To Performance Standard. e. Sponsor May Appeal Denial Order To Special Panel. f. Special Panel Decision May Be Appealed To Court. 1. Review Of The PMA In Pieces Or Modules. 2. Allows For Closure Of One Or More Modules Before PMA Is Submitted (e.g., manufacturing information). 3. PMA Shell Outline of Sections. 5

6 4. Guidance for Industry: Guidances for the Medical Device Industry on PMA Shell Development and Modular Review (Nov. 6, 1998) [Exhibit 3]. L. Use And Availability Of PMA Data. 1. FDAMA Repealed "Four-Of-A-Kind" Rule For Release of PMA Data By Which Certain Clinical And Preclinical Test Data Compiled To Prove Safety And Effectiveness Would Become Available For Use By The Agency One Year After The Application For The Fourth Device "Of A Kind" Is Approved. This Rule Is Replaced With A Similar Provision By Which The Data Is Available Six Years After The Approval Of The Application That Is The Source Of The Data. Note: method of manufacture and composition of material remains confidential. Note: FDA has never declared that four devices "of a kind have been approved. 2. PMA Guidances -- FDA Has Published Guidances On Various Devices And Testing Protocols For Devices. M. Dispute Resolution Process. See Guidance: Resolving Scientific Disputes concerning the Regulation of Medical Devices, A Guide to Use of The Medical Devices Dispute Resolution Panel, (7/2/01) [Exhibit 4]. II. MAKING CHANGES TO PMA APPROVED DEVICES PMA SUPPLEMENTS A. Device Changes Affecting Safety Or Effectiveness Require Approval Of A PMA Supplement (21 C.F.R ). 1. Examples Of Changes That Require A Supplement If Affecting Safety Or Effectiveness: a. New Indications For Use; b. Labeling Changes; c. Change in Manufacturing, Processing, Or Packaging Facility; d. Changes In Sterilization Procedures; e. Changes In Packaging; f. Changes In Specifications, Circuits, Components, Ingredients, Principle Of Operation, Or Physical Layout; or 6

7 g. Extension Of Expiration Date Based On Data From An Unapproved Stability Protocol. 2. PMA Holder s Obligation To Determine If A Supplement Is Required. Draft Guidance: Guidance for Industry: Modifications To Devices Subject to Premarket Approval The PMA Supplement Decision Making Process (Aug. 6, 1998) [Exhibit 5] Day Review Period. B. Special PMA Supplement Changes Being Effected Used For Changes That Enhance Safety. 21 C.F.R (d) 1. Do Not Have To Wait For FDA Approval, But Must Wait For Acknowledgment. 2. May Be Used For The Following Changes: a. Strengthening Of Warnings, Contraindications, Or Precautions; b. Adding Or Strengthening An Instruction Intended To Enhance The Safe Use Of The Device; c. Deletion Of Misleading, False, Or Unsupported Indications; d. Quality Control Changes That Provide Additional Assurance Of Purity, Identity, Strength, Or Reliability. C. 30-Day Notice Used For Changes In Manufacturing That Affect Safety And Effectiveness. FDCA 515(d)(6); 21 C.F.R (f). 1. Notify FDA Of A Modification To The Manufacturing Procedures Made In Accordance With QSRs. 2. May Implement Change 30 Days After FDA Receives The Notice Unless FDA Notifies The Manufacturer That The Notice Is Inadequate. 3. If A PMA Supplement Is Required Time Under Review As A 30-Day Notice Is Subtracted From The 135 Day Review Period. D. Changes That Do Not Affect Safety Or Effectiveness Can Be Documented In File Or, If Required By FDA, Reported In Annual (or Periodic) Reports. III. PRODUCT DEVELOPMENT PROTOCOLS (PDP) A. Alternative To Submission Of PMA. 7

8 B. FDA And Applicant Reach Pre-Application Agreement As To Data Requirements For Approval Of Device. Completion Of Protocol Results In Approval Of Device. C. FDA Has Not Issued Regulations. D. FDA Draft Guidance, Contents Of A Product Development Protocol (5/14/98) (Full Text Available At [ E. Usually Works Best for Devices Already Well Understood By FDA. IV. HUMANITARIAN DEVICE EXEMPTION (HDE) (FDCA 520(m); 21 C.F.R. Part 814, Subpart H) A. Allows Marketing Of A Humanitarian Use Device (HUD) Without Reasonable Assurance Of Effectiveness. B. Limited To Devices Intended To Benefit Patients In The Treatment Or Diagnosis Of Diseases Or Conditions That Affect Or Are Manifested In Fewer Than 4,000 Individuals In The U.S. Per Year. C. Amount Charged For The Device Cannot Exceed The Costs Of the Research, Development, Fabrication, And Distribution. D. After Approval, Must Periodically Provide Detailed Information On Cost, Safety, And Continued Justification For HUD Status. E. Must Be Used Only Under The Review Of An Institutional Review Board ( IRB ). 8

PMAs, 510(k)s, and Advanced IDE Topics

PMAs, 510(k)s, and Advanced IDE Topics PMAs, 510(k)s, and Advanced IDE Topics Kenneth J. Cavanaugh Jr., Ph.D. Scientific Reviewer Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health kenneth.cavanaugh@fda.hhs.gov

More information

IVD Regulation Overview. Requirements to Assure Quality & Effectiveness

IVD Regulation Overview. Requirements to Assure Quality & Effectiveness IVD Regulation Overview Requirements to Assure Quality & Effectiveness CLIAC Jan. 2002 Statutory and Regulatory Requirements Statute: Food, Drug, and Cosmetic Act Food and Drugs Act of 1906 Food and Drug

More information

Guidance on IDE Policies and Procedures

Guidance on IDE Policies and Procedures Guidance on IDE Policies and Procedures This document is intended to provide guidance. It represents the Agency s current thinking on the above. It does not create or confer any rights for or on any person

More information

Guidance for Industry and Food and Drug Administration Staff

Guidance for Industry and Food and Drug Administration Staff Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff Guidance for Industry and Food and Drug Administration Staff Document

More information

Humanitarian Use Devices for Clinical Treatment or Diagnosis

Humanitarian Use Devices for Clinical Treatment or Diagnosis Humanitarian Use Devices for Clinical Treatment or Diagnosis Content Applies To Mayo Clinic Human Research Protection Program Relying Organizations for which Mayo Clinic IRB is the IRB of Record Purpose

More information

U.S. Food and Drug Administration (FDA) Regulatory Pathways for Medical Devices

U.S. Food and Drug Administration (FDA) Regulatory Pathways for Medical Devices Lisa L. Michels General Counsel & Regulatory Expert Susan J. Schniepp, Distinguished Fellow Regulatory Compliance Associates Inc. U.S. Food and Drug Administration (FDA) Regulatory Pathways for Medical

More information

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office

More information

FDAnews Webinar. Dan Kracov and Dan Pariser Arnold & Porter LLP. December 9, Copyright 2013 by Arnold & Porter LLP

FDAnews Webinar. Dan Kracov and Dan Pariser Arnold & Porter LLP. December 9, Copyright 2013 by Arnold & Porter LLP FDAnews Webinar Overview and Implications: The Food and Drug Administration s Proposal to Permit Generic Drug Manufacturers to Initiate Labeling Changes Dan Kracov and Dan Pariser Arnold & Porter LLP December

More information

ORACLE CONSULTING GROUP

ORACLE CONSULTING GROUP ORACLE CONSULTING GROUP An Official United States Agent Firm for Foreign Establishments CONSULTING MEMORANDUM: DEALING WITH A MEDICAL DEVICE IN THE U.S. 5398 Golder Ranch Rd., Ste. 1 Tucson, Arizona 85739

More information

Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program

Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes

More information

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special

More information

JUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807

JUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JUL 2 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular

More information

Overview of FDA Compliance for Medical Devices

Overview of FDA Compliance for Medical Devices Glisland Training Series: Overview of FDA Compliance for Medical Devices Glisland, Inc. San Jose, California, USA http://www.glisland.com Description This course provides a concise overview of how FDA

More information

Guidance for Industry

Guidance for Industry Guidance for Industry FDA Export Certificates Submit comments and suggestions regarding this document at anytime to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane,

More information

Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA

Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions

More information

FDA Regulation of Medical Devices

FDA Regulation of Medical Devices FDA Regulation of Medical Devices Bradley Merrill Thompson Interpharm Press, Inc. Buffalo Grove, IL Dedication Acknowledgments Introduction xv xvi xvii Part I. Overview Chapter 1. The History of Medical

More information

Clinical evaluation Latest development in expectations EU and USA

Clinical evaluation Latest development in expectations EU and USA Clinical evaluation Latest development in expectations EU and USA Medical Devices: staying ahead of regulatory developments Gert Bos BSI Israel 22 April - Herzliya Copyright 2012 BSI. All rights reserved.

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Formal Dispute Resolution: Appeals Above the Division Level Additional copies of this Guidance are available from: Office of Training and Communications Division of Communications

More information

Guidance for Industry Classifying Resubmissions in Response to Action Letters

Guidance for Industry Classifying Resubmissions in Response to Action Letters Guidance for Industry Classifying Resubmissions in Response to Action Letters U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug

More information

21st Century Cures Act: Key Provisions Related to Medical Devices

21st Century Cures Act: Key Provisions Related to Medical Devices 21st Century Cures Act: Key Provisions Related to Medical Devices July 30, 2015 Food & Drug The 21st Century Cures Act ( the Act or HR 6 ) was passed by the House of Representatives on July 10, 2015, by

More information

Good Clinical Practice 101: An Introduction

Good Clinical Practice 101: An Introduction Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological

More information

Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols

Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols For questions on the content of this document contact Leonard Wilson, CBER at 301-827-0373 or Susan Johnson, CDER

More information

FY 2011 Medical Device User Fee Small Business Qualification and Certification

FY 2011 Medical Device User Fee Small Business Qualification and Certification Guidance for Industry, FDA, and Foreign Governments: FY 2011 Medical Device User Fee Small Business Qualification and Certification Document issued August 2, 2010 As of September 1, 2010, this document

More information

Presented by: Edward Basile

Presented by: Edward Basile Presented by: Edward Basile THE FDC ACT S DEFINITION OF LABELING Labeling (21 U.S.C. 321(m)) All written, printed, or graphic matter upon an article or container or accompanying such article. Generally,

More information

Page 191 TITLE 21 FOOD AND DRUGS 355 1

Page 191 TITLE 21 FOOD AND DRUGS 355 1 Page 191 TITLE 21 FOOD AND DRUGS 355 1 APPEALS TAKEN PRIOR TO OCTOBER 10, 1962 Section 104(d)(3) of Pub. L. 87 781 made amendments to subsec. (h) of this section inapplicable to any appeal taken prior

More information

Reporting Changes to an Approved NDA or ANDA

Reporting Changes to an Approved NDA or ANDA Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Reporting Changes to an Approved NDA or ANDA SNMMI Annual Meeting - June 8, 2015 Michael Nazerias Sr. Director RA/QA PETNET Solutions,

More information

Regulatory Science and Translational Research Clinical Trials for Medical Devices What do you need to know?

Regulatory Science and Translational Research Clinical Trials for Medical Devices What do you need to know? Regulatory Science and Translational Research Clinical Trials for Medical Devices What do you need to know? Lynn M. Rose, PhD Research Associate Professor, Pediatrics Institute of Translational Health

More information

UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM. DoD/DON-funded Research

UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM. DoD/DON-funded Research UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM DoD/DON-funded Research Policy In 2006, the Department of the Navy (DON) enhanced its human subject protection requirements, including

More information

Draft Guidance for Industry and FDA Staff. In Vitro Diagnostic (IVD) Device Studies Frequently Asked Questions

Draft Guidance for Industry and FDA Staff. In Vitro Diagnostic (IVD) Device Studies Frequently Asked Questions Draft Guidance for Industry and FDA Staff In Vitro Diagnostic (IVD) Device Studies Frequently Asked Questions This guidance document is being distributed for comment purposes only. Document issued on:

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Jabones Pardo S.A.

More information

Combination Products Regulation in the United States

Combination Products Regulation in the United States Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction

More information

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry Reprinted from FDA s website by EAS Consulting Group, LLC ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry DRAFT GUIDANCE This guidance document

More information

February 2006 Procedural

February 2006 Procedural Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and

More information

Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions

Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration

More information

Refuse to Accept Policy for 510(k)s. Guidance for Industry and Food and Drug Administration Staff

Refuse to Accept Policy for 510(k)s. Guidance for Industry and Food and Drug Administration Staff Refuse to Accept Policy for 510(k)s Guidance for Industry and Food and Drug Administration Staff Document issued on: December 31, 2012 This document supersedes Center for Devices and Radiological Health

More information

David M. Stern, M.D. JAN 2 9 7007 Dean, University of Cincinnati College of Medicine 231 Albert Sabin Way Cincinnati, OH 45267

David M. Stern, M.D. JAN 2 9 7007 Dean, University of Cincinnati College of Medicine 231 Albert Sabin Way Cincinnati, OH 45267 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Serv ice Food and Drug Administration 9200 Corporate Boulevard Rockville, Ma ry land 20850 WARNING LETTER VIA FEDERAL EXPRESS David M. Stern, M.D. JAN

More information

UW MEDICINE IDE/HDE DEVICE COVERAGE AND BILLING MAY, 2013

UW MEDICINE IDE/HDE DEVICE COVERAGE AND BILLING MAY, 2013 UW MEDICINE IDE/HDE DEVICE COVERAGE AND BILLING MAY, 2013 DEFINITIONS Investigational Device Exemption (IDE)- An approved IDE means that an IRB (and FDA for significant risk devices) has approved the sponsor

More information

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE This guidance document

More information

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Total Product Lifecycle Solutions from NSF Health Sciences Medical Devices

Total Product Lifecycle Solutions from NSF Health Sciences Medical Devices Total Product Lifecycle Solutions from NSF Health Sciences Medical Devices Experts in medical device quality systems, compliance, regulatory affairs, auditing and training www.nsf.org The Right People.

More information

August 18, 2015. Re: Section 1201 Rulemaking Proposed Exemption for Medical Devices

August 18, 2015. Re: Section 1201 Rulemaking Proposed Exemption for Medical Devices DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 August 18, 2015 Ms. Jacqueline C. Charlesworth General Counsel

More information

How to Manage Regulatory Issues and get FDA Approvals

How to Manage Regulatory Issues and get FDA Approvals How to Manage Regulatory Issues and get FDA Approvals Maureen Garner, President Glenn Neuman, Director of Scientific Affairs New World Regulatory Solutions, Inc. www.newworldreg.com 1 About NWRS New World

More information

Document issued on: March 19, The draft of this document was issued on May 20, 2010.

Document issued on: March 19, The draft of this document was issued on May 20, 2010. Guidance for Industry, Third Parties and Food and Drug Administration Staff Medical Device ISO 13485:2003 Voluntary Audit Report Submission Pilot Program Document issued on: March 19, 2012 The draft of

More information

THE FOOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007

THE FOOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 THE FOOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 LIETZAN, LABSON AND SCOTT : THE FOOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 : [2006/2007] 2 BSLR 39 further in future years, subject to certain

More information

August 21, 2015. TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom

August 21, 2015. TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Mr. Iain Alligan Technical

More information

In vitro Device Regulation

In vitro Device Regulation In vitro Device Regulation Molecular Pathologists Reagent (Analyte) Manufacturers High Complexity Clinical Labs Commercial Academic in Vitro Diagnostics Manufacturers Drug Developers large & small 2 States

More information

) 1 1 > 1 FDA Docket No. 02H-0443 1 ) ) ) ) 1 1 ) 1 )

) 1 1 > 1 FDA Docket No. 02H-0443 1 ) ) ) ) 1 1 ) 1 ) UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES In the matter of LAHAYE CENTER FOR ADVANCED EYE CARE OF LAFAYETTE, D/B/A LAHAYE TOTAL EYE CARE,

More information

Regulatory Requirements for Clinical Studies of Medical Devices and Diagnostics

Regulatory Requirements for Clinical Studies of Medical Devices and Diagnostics Regulatory Requirements for Clinical Studies 21 2 Regulatory Requirements for Clinical Studies of Medical Devices and Diagnostics Daniel A. Kracov and Lisa M. Dwyer 1. Introduction The investigational

More information

In Vitro Diagnostic (IVD) Devices: How they Differ from Other Devices and How FDA Regulates Them

In Vitro Diagnostic (IVD) Devices: How they Differ from Other Devices and How FDA Regulates Them In Vitro Diagnostic (IVD) Devices: How they Differ from Other Devices and How FDA Regulates Them IRB Education Conference, Columbia University April 2007 Sally Hojvat, Ph.D. Director of Microbiology Devices

More information

The Health Insurance Portability and Accountability Act (HIPAA) Excerpted from the UTC IRB Policy

The Health Insurance Portability and Accountability Act (HIPAA) Excerpted from the UTC IRB Policy The Health Insurance Portability and Accountability Act (HIPAA) Excerpted from the UTC IRB Policy June 2008 Table of Contents PART V: The Health Insurance Portability and Accountability Act (HIPAA)...

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,

More information

DICOM Grid, Inc. January 25, 2016. Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314

DICOM Grid, Inc. January 25, 2016. Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 DICOM Grid, Inc. Senior

More information

TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H--MEDICAL DEVICES

TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H--MEDICAL DEVICES [Code of Federal Regulations] [Title 21, Volume 8] [Revised as of April 1, 2010] [CITE: 21CFR807] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES

More information

4. No accounting of disclosures is required with respect to disclosures of PHI within a Limited Data Set.

4. No accounting of disclosures is required with respect to disclosures of PHI within a Limited Data Set. IDAHO STATE UNIVERSITY POLICIES AND PROCEDURES (ISUPP) HIPAA Privacy - Limited Data Sets and Data Use Agreements 10200 POLICY INFORMATION Major Functional Area (MFA): MFA X - Office of General Counsel

More information

THE FREEDOM OF INFORMATION ACT A User s Guide

THE FREEDOM OF INFORMATION ACT A User s Guide THE FREEDOM OF INFORMATION ACT A User s Guide By The Freedom of Information Clearinghouse A Project of Ralph Nader (Revised 11/05) The Freedom of Information Act ( FOIA ) was enacted by Congress in 1966

More information

February 5, 2015. Dear Kristin Pabst,

February 5, 2015. Dear Kristin Pabst, DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 February 5, 2015, Inc.

More information

Clinical Trial Billing Compliance under Medicare February 12-13, Pier 5 Hotel, Baltimore, MD

Clinical Trial Billing Compliance under Medicare February 12-13, Pier 5 Hotel, Baltimore, MD Clinical Trial Billing Compliance under Medicare February 12-13, Pier 5 Hotel, Baltimore, MD Medicare Coverage with Evidence Development and Potential Impact on Your Clinical Trial Policy Kirk L. Dobbins,

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Promoting Medical Products in a Changing Healthcare Environment; I. Medical Product Promotion by Healthcare Organizations or Pharmacy Benefits Management Companies (PBMs) DRAFT GUIDANCE

More information

Guidance for Industry

Guidance for Industry Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center

More information

MEDICAL DEVICE REGULATIONS IN THE U.S. THE BASICS

MEDICAL DEVICE REGULATIONS IN THE U.S. THE BASICS MEDICAL DEVICE REGULATIONS IN THE U.S. THE BASICS This paper is a general summary of food and medical device regulations administered by the U.S. Food and Drug Administration (FDA). There may be other

More information

Guidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions

Guidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions Guidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions U.S. Department of Health and Human Services Food and Drug Administration Center for

More information

January 12, 2016. Dear Amy Yang:

January 12, 2016. Dear Amy Yang: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 January 12, 2016 Amy

More information

Quality System: Design Control Procedure - Appendix

Quality System: Design Control Procedure - Appendix Quality System: Design Control Procedure - Appendix Page 1 of 10 Quality System: Design Control Procedure - Appendix CORP Medical Products Various details have been removed, indicated by [ ] 1. Overview

More information

Investigational Drugs: Investigational Drugs and Biologics

Investigational Drugs: Investigational Drugs and Biologics : I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place

More information

ABBREVIATED NEW DRUG APPLICATION (ANDA)

ABBREVIATED NEW DRUG APPLICATION (ANDA) CHAPTER-II ABBREVIATED NEW DRUG APPLICATION (ANDA) by: j. jayasutha lecturer department of pharmacy practice Srm college of pharmacy srm university ABBREVIATED NEW DRUG APPLICATION INTRODUCTION ANDA is

More information

Guidance for Industry and FDA Staff Tonometers - Premarket Notification [510(k)] Submissions

Guidance for Industry and FDA Staff Tonometers - Premarket Notification [510(k)] Submissions Guidance for Industry and FDA Staff Tonometers - Premarket Notification [510(k)] Submissions Document issued on: March 27, 2006 For questions regarding this document, contact Everette Beers, Ph.D. at 240-276-4200

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Major, Minor, and Telephone Amendments to Abbreviated New Drug Applications Comments and suggestions regarding this document should be submitted within 90 days of publication in the

More information

Department of Defense INSTRUCTION

Department of Defense INSTRUCTION Department of Defense INSTRUCTION NUMBER 6200.02 February 27, 2008 SUBJECT: Application of Food and Drug Administration (FDA) Rules to Department of Defense Force Health Protection Programs USD(P&R) References:

More information

Client Alert. Supreme Court Rules State Law Tort Claims Involving Drug Labels Approved by FDA Are Not Preempted

Client Alert. Supreme Court Rules State Law Tort Claims Involving Drug Labels Approved by FDA Are Not Preempted Contact Attorney Regarding This Matter: Jennifer S. Blakely 404.873.8734 - direct 404.873.8735 - fax jennifer.blakely@agg.com William H. Kitchens 404.873.8644 - direct 404.873.8645 - fax william.kitchens@agg.com

More information

How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters

How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters environmental failure analysis & prevention health technology development How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters Kevin L. Ong, Ph.D., P.E. Managing

More information

SUPPORTING STATEMENT FOR Hearing Aid Devices, Professional and Patient Labeling and Conditions for Sale 21 CFR 801.420 and 801.421 OMB No.

SUPPORTING STATEMENT FOR Hearing Aid Devices, Professional and Patient Labeling and Conditions for Sale 21 CFR 801.420 and 801.421 OMB No. A. JUSTIFICATION SUPPORTING STATEMENT FOR Hearing Aid Devices, Professional and Patient Labeling and Conditions for Sale 21 CFR 801.420 and 801.421 OMB No. 0910-0171 1. Circumstances Making the Collection

More information

Chapter 8 WHAT THE STATUTE AND REGULATIONS SAY. Combination Products. Key Points

Chapter 8 WHAT THE STATUTE AND REGULATIONS SAY. Combination Products. Key Points Chapter 8 Combination Products Suzanne O Shea, Baker & Daniels, LLP, Indianapolis, IN Key Points A combination product comprises two or more different types of regulated components. It can be a drug/device,

More information

Clinical trials for medical devices: FDA and the IDE process

Clinical trials for medical devices: FDA and the IDE process Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,

More information

Q(K SVJM~jPagelIof 3

Q(K SVJM~jPagelIof 3 K13 0460 Q(K SVJM~jPagelIof 3 JUL 1 12013 This 51 0(k) Summary is being submitted in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content contained in this 510(k)

More information

State of Wisconsin Department of Children and Families DCF 105. Substance Abuse Screening and Testing for Certain Department Work Experience Programs

State of Wisconsin Department of Children and Families DCF 105. Substance Abuse Screening and Testing for Certain Department Work Experience Programs State of Wisconsin Department of Children and Families DCF 105 Substance Abuse Screening and Testing for Certain Department Work Experience Programs The Wisconsin Department of Children and Families proposes

More information

ATLANTIS Anterior Cervical Plate System ATLANTIS Translational Plate. 510(k) Summary. February 2007

ATLANTIS Anterior Cervical Plate System ATLANTIS Translational Plate. 510(k) Summary. February 2007 rk,1 10{2 ATLANTIS Anterior Cervical Plate System ATLANTIS Translational Plate 510(k) Summary FEB 2 3 2[007 February 2007 I. Company: Medtronic Sofamor Danek USA 1800 Pyramid Place Memphis, Tennessee 38132

More information

Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff

Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Document issued on August 20, 2014. On November 5, 2014 this document was

More information

Use of Standards in the Food and Drug Administration's Regulatory Oversight of Next

Use of Standards in the Food and Drug Administration's Regulatory Oversight of Next This document is scheduled to be published in the Federal Register on 07/08/2016 and available online at http://federalregister.gov/a/2016-16201, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Getting CMS Reimbursement for Medical Technology Products

Getting CMS Reimbursement for Medical Technology Products FDLI & Clinical Device Group September 7, 2006 Getting CMS Reimbursement for Medical Technology Products Reimbursement for Medical Technology, Overview of CMS Coverage Kirk L. Dobbins, Esq. Difference

More information

Roles & Responsibilities of the Sponsor

Roles & Responsibilities of the Sponsor Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from

More information

Charging for Investigational Drugs Under an Investigational New Drug Application--Questions

Charging for Investigational Drugs Under an Investigational New Drug Application--Questions This document is scheduled to be published in the Federal Register on 06/03/2016 and available online at http://federalregister.gov/a/2016-13166, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Datrix, Inc NOV - 1 2005. Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System

Datrix, Inc NOV - 1 2005. Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System Appendix G NOV - 1 2005 510(k) Summary of Safety and Effectiveness for CardioServer ECG Management System 1. DATE SUMMARY PREPARED: 9-26-2005 2. SUBMITTER'S NAME AND ADDRESS: Linda Gluckman 340 State Place

More information

Triangle Compounding 11/2/15

Triangle Compounding 11/2/15 Triangle Compounding 11/2/15 Department of Health and Human Services Public Health Service Food and Drug Administration Atlanta District 60 Eighth Street NE Atlanta, GA 30309 November 2, 2015 VIA UNITED

More information

Contains Nonbinding Recommendations

Contains Nonbinding Recommendations FY 2016 Medical Device User Fee Small Business Qualification and Certification Guidance for Industry, Food and Drug Administration Staff and Foreign Governments Document issued on August 3, 2015. As of

More information

Reliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s)

Reliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s) Name of Organization Providing IRB Review: Stony Brook University ( SBU IRB ) Name of Institution Relying on the SBU IRB ( Institution ): Latest AAHRPP Accreditation Date (if applicable) OHRP Federal Wide

More information

DEPARTMENT OF HEALTH CARE FINANCE

DEPARTMENT OF HEALTH CARE FINANCE DEPARTMENT OF HEALTH CARE FINANCE Dear Provider: Enclosed is the District of Columbia Medicaid provider enrollment application solely used for providers, who request to be considered for the Adult Substance

More information

BUSINESS ASSOCIATE ADDENDUM

BUSINESS ASSOCIATE ADDENDUM BUSINESS ASSOCIATE ADDENDUM This BA Agreement, effective as of the effective date of the Terms of Use, adds to and is made part of the Terms of Use by and between Business Associate and Covered Entity.

More information

IRB Process & Medical Devices. Sandra Rogers IRB Pacific University

IRB Process & Medical Devices. Sandra Rogers IRB Pacific University + IRB Process & Medical Devices Sandra Rogers IRB Pacific University + IRB Review of Research: Criteria n Informed Consent (Respect for Persons) n Will be sought prospectively n Includes required elements

More information

The draft of this document issued on December 27, 2011.

The draft of this document issued on December 27, 2011. The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)] Guidance for Industry and Food and Drug Administration Staff Document issued on: July 28, 2014 The draft of this

More information

Contains Nonbinding Recommendations

Contains Nonbinding Recommendations Guidance for Industry and FDA Staff Laser Products Conformance with IEC 60825-1 and IEC 60601-2-22; Guidance for Industry and FDA Staff (Laser Notice No. 50) Document issued on June 24, 2007 This document

More information

State and Territory Coastal Management Program Managers

State and Territory Coastal Management Program Managers MEMORANDUM FOR: FROM: SUBJECT: State and Territory Coastal Management Program Managers Jeffrey R. Benoit Director Final Program Change Guidance Attached is the Office of Ocean and Coastal Resource Management

More information

CHAPTER 172. C.56:11-28 Short title. 1. This act shall be known and may be cited as the "New Jersey Fair Credit Reporting Act."

CHAPTER 172. C.56:11-28 Short title. 1. This act shall be known and may be cited as the New Jersey Fair Credit Reporting Act. CHAPTER 172 AN ACT concerning consumer credit reports and supplementing Title 56 of the Revised Statutes. BE IT ENACTED by the Senate and General Assembly of the State of New Jersey: C.56:11-28 Short title.

More information

[DOCKET NO.96N-0002] DRAFT

[DOCKET NO.96N-0002] DRAFT [DOCKET NO.96N-0002] DRAFT DRAFT DOCUMENT CONCERNING THE REGULATION OF PLACENTAL/UMBILICAL CORD BLOOD STEM CELL PRODUCTS INTENDED FOR TRANSPLANTATION OR FURTHER MANUFACTURE INTO INJECTABLE PRODUCTS DECEMBER,

More information

PREP Course #27: Medical Device Clinical Trial Management

PREP Course #27: Medical Device Clinical Trial Management PREP Course #27: Medical Device Clinical Trial Management Presented by: Evelyn Huang Jeffrey Revello Office of Research Compliance North Shore-LIJ Health System CME Disclosure Statement The North Shore

More information

Food and Drug Administration Center for Device and WARNING LETTER

Food and Drug Administration Center for Device and WARNING LETTER ra Scavicrs r ~. ~~ DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service a ` o ~"`3w1~,Y d 3t) Food and Drug Administration Center for Device and Radiological Health 9200 Corporate Blvd. Rockville,

More information

Koqo8 go. ER35 ERO-SCAN Pro Hearing Test System. 61 Martin Lane Elk Grove Village, IL 60007. Manager of Instrumentation Products

Koqo8 go. ER35 ERO-SCAN Pro Hearing Test System. 61 Martin Lane Elk Grove Village, IL 60007. Manager of Instrumentation Products Koqo8 go Traditional 510(k) Premarket Notification ER35 ERO-SCAN Pro Hearing Test System Page 6 3.0 510(K) SUMMARY Submission Date: March 30, 2007 Submitter Information: Company Name: Company Address:

More information

Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice

Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Kurt R. Karst Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, D.C.

More information

ALTERNATIVE TRADING SYSTEM RULES

ALTERNATIVE TRADING SYSTEM RULES ALTERNATIVE TRADING SYSTEM RULES (text according to legal condition at 20 June 2012) 1 NOTE: Only the Polish version of this document is legally binding. This translation is provided for information only.

More information

Specialty Medicine Compounding Pharmacy, P.C. 8/31/15

Specialty Medicine Compounding Pharmacy, P.C. 8/31/15 Specialty Medicine Compounding Pharmacy, P.C. 8/31/15 Department of Health and Human Services Public Health Service Food and Drug Administration Detroit District 300 River Place Suite 5900 Detroit, Ml

More information